Mana.bio is an AI based drug delivery startup, focusing on gene therapy including DNA and RNA-based therapeutics, and vaccines. We are on a mission to disrupt the drug delivery space using combined forces of machine learning and nanotechnology.
Mana.bio is creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.
Operator of an AI-based drug delivery company intended to facilitate lipid nanoparticle development for oligonucleotide therapies. The company uses technology powered by the integration of machine learning and nanotechnology in order to identify formulations of lipid nanoparticle systems and focus on gene therapy including DNA and RNA-based therapeutics, and vaccines, enabling healthcare industry to get a better drug delivery service.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2021
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Mana.bio
Yogev Debbi
Co-Founder & Chief Executive Officer
